Evidence map›Paper›PMID 42742406›Full record

ReviewCNS neuroscience & therapeutics2026

NG2-Glia in Central Nervous System Following Injury: From Pathological Involvement to Repair Potential.

Yunyun Cai, Xin Shen, Ming Li, Junjie Li, Gang Chen

Abstract readReview
In one paragraph

Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yunyun CaiDepartment of Histology and Embryology, Medical School of Nantong University, Co-Innovation Center of Neuroregeneration, Nantong, Jiangsu, China.ORCID https://orcid.org/0000-0002-7831-0936
Xin ShenDepartment of Histology and Embryology, Medical School of Nantong University, Co-Innovation Center of Neuroregeneration, Nantong, Jiangsu, China.
Ming LiDepartment of Histology and Embryology, Medical School of Nantong University, Co-Innovation Center of Neuroregeneration, Nantong, Jiangsu, China.
Junjie LiDepartment of Histology and Embryology, Medical School of Nantong University, Co-Innovation Center of Neuroregeneration, Nantong, Jiangsu, China.
Gang ChenDepartment of Histology and Embryology, Medical School of Nantong University, Co-Innovation Center of Neuroregeneration, Nantong, Jiangsu, China.ORCID https://orcid.org/0000-0003-3669-5687

Funding

The National Natural Science Foundation of China 32271054The National Natural Science Foundation of China 32571189
6 · The paper itself

Abstract

backgroundCentral nervous system (CNS) injury remains a severe neurological condition with limited regenerative capacity. NG2-glia are abundant and functionally versatile glial cells that have attracted increasing attention in CNS repair research. However, their roles are complex and context-dependent, ranging from early pathological involvement to later reparative potential, and a systematic synthesis of this temporal dichotomy is lacking.

methodWe systematically searched PubMed and Web of Science from inception to 2026 using combinations of keywords including "NG2-glia," "NG2 cells," "oligodendrocyte precursor cells," "OPCs," and "CNS injury." Additional references were identified by manual screening of reference lists. We prioritized mechanistic and therapeutic studies published within the last 10 years, while foundational discoveries were included for historical context.

resultsThis review establishes that NG2-glia exhibit a time-dependent dual role after CNS injury. In the early stage (hours to days), they rapidly proliferate, migrate to the lesion, and secrete chondroitin sulfate proteoglycans (CSPGs), forming a chemical and physical barrier that inhibits axonal regeneration and may facilitate neuropathic pain. In the middle-to-late stages (days to weeks/months), they shift toward repair functions, including remyelination via differentiation into oligodendrocytes, neuronal trans-differentiation (primarily under forced reprogramming), and anti-inflammatory/neuroprotective effects through interactions with microglia, astrocytes, and neurons. Their fate is determined by intrinsic factors (age, heterogeneity) and extrinsic microenvironmental signals (damage-associated molecules, cytokines, and signaling pathways such as Wnt/β-catenin and TGF-β2). Therapeutically, diverse strategies-including CB1 receptor agonists to promote remyelination, chondroitinase ABC to neutralize CSPG inhibition, and SOX2/NeuroD1-based reprogramming to generate functional neurons-have shown preclinical promise, yet significant translational gaps remain, including poor endogenous neurogenesis, constitutive differentiation limitations, and safety concerns. CONCLUSION AND PERSPECTIVE: Targeting NG2-glia offers a novel avenue for CNS repair, but successful interventions must be precisely timed and stage-specific rather than unregulated promotion or inhibition. This review proposes an analytical framework of "time-dependent dual roles" to reconcile the contradictory functions of NG2-glia and highlights critical future directions, including deciphering regional heterogeneity, elucidating the molecular switches that govern state transitions, validating the functional integration of reprogrammed neurons, and bridging the bench-to-bedside divide. A deeper understanding of the regulatory logic underlying NG2-glia plasticity will inform next-generation precision therapies for CNS injuries.

Indexed as

Central Nervous SystemCentral Nervous System DiseasesNerve RegenerationNeurogliaOligodendrocyte Precursor CellsAnimalsAntigensChondroitin Sulfate Proteoglycan 4HumansAntigensChondroitin Sulfate Proteoglycan 4CNS injuryglial cellsimmune regulatoryneuronNG2‐gliarepair

Identifiers

PMID42742406
PMCPMC13576928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.